Disintoxication infusion solution "neoreodez"

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and pharmacy and can be applied in production and application of solutions for intravenous introduction in treatment of conditions, associated with endogenous intoxication. Disintoxication solution contains components in the following ratio (wt %): sodium hypochlorite 0.04-0.08, sodium chloride 0.50-1.00, aminoethane sulfonic acid 0.02-1.20.

EFFECT: novel infusion solution is claimed.

4 ex, 1 tbl

 

The invention relates to medicine and pharmacy and can be used in the production and application of solutions for intravenous administration in the treatment of conditions associated with endogenous intoxication, for example, if:

bacterial sepsis of newborn;

- postpartum sepsis;

- purulent peritonitis;

- suppurative pancreatitis;

thermal and chemical burns;

- destruction of the organs of the abdominal cavity, and other.

Closest to the solution that is suggested is the solution according to the patent of Ukraine No. 8932, the composition of which: 0.06% sodium hypochlorite with the addition of the trylon B and sodium chloride at a ratio of components, wt.%:

Trilon B0,0475-0,0525
Sodium chloride0,855-0,945
0,06% solution of sodium hypochloriterest

This famous similar in essential characteristics that coincide with the inventive solution makes it possible to accept it as a prototype.

The essential features of the prototype and the proposed solution, which coincide, is that the solution contains chloride and sodium hypochlorite. The lack of a solution for the prototype is that its stability is ity at room temperature is not sufficient for General use.

Task to be achieved by the claimed solution is to maintain the concentration of active chlorine within its therapeutic action in a period sufficient to use the solution in wide clinical practice.

The problem is solved in that in detoxification solution instead of trylon B is used aminoetansulfonovaya acid with a ratio of components, wt.%:

Sodium hypochlorite0,04-0,08
Sodium chloride0,50-1,00
Aminoetansulfonovaya acid0,02-1,20

A causal relationship between a set of features that are announced, is the following. Adding aminoethanesulfonic acid in the equilibrium formation of N-chloromycetinultra acid inhibits the decomposition of hypochlorite ion by the reaction of its interaction with water, in addition aminoetansulfonovaya acid shows a wide spectrum of biological actions primarily in the metabolic processes of carbohydrate and protein metabolism, maintenance of homeostasis of intracellular concentration of calcium and sodium in the regulation of cell volume is mA stabilization of cell membranes, neuromodulation, vasodilation, cardiac activity, the processes of learning and memory, provides anti-atherogenic and anti-hypertensive effects, takes part in the development of brain and retina, protects visual function in diabetes and improves the function of the immune system, shows antitoxin and anti-inflammatory effects, inhibiting the proliferation of tumour cells, protects other organs from damage, including psychological and oxidative stress provides cardioprotective effects in ischemia-reperfusion, in addition, being an endogenous substance of the body, taurine is not associated with toxicity or medical dependence and well tolerated in clinical use.

The following examples demonstrate the positive effect of aminoethanesulfonic acid on the stability of the solution.

Adding aminoethanesulfonic acid to the corresponding solutions of chloride and sodium hypochlorite were made following solutions, wt.%:

Solution 1

/table>

Solution 2

Sodium hypochlorite0,04
Sodium chloride0,50
Aminoetansulfonovaya acid0,05
Sodium hypochlorite0,08
Sodium chloride0,70
Aminoetansulfonovaya acid1,20

A solution of 3

Sodium hypochlorite0,06
Sodium chloride1,00
Aminoetansulfonovaya acid0,08

As the reference solution used solution-prototype:

A solution of 4

Trilon B0,06
Sodium chloride0,9
Sodium hypochlorite0,06

The results of stability testing of solutions (wt.% sodium hypochlorite) is shown in the table below. The solutions were kept at 20-25°C.

The time from the beginning of the test, monthsSolution 1Solution 2 Solution 3A solution of 4
00,040,080,060,06
10,0380,0790,0590,051
20,0370,0760,0540,038
30,0370,0750,0510,024
60,0310,0680,0480,009

The results show a positive effect claimed as the invention of the solution.

Detoxifying infusion solution, which contains sodium hypochlorite and sodium chloride, characterized in that it further comprises aminoethanesulfonic acid with a ratio of components, wt.%:

Sodium hypochlorite0,04-0,08
Sodium chloride 0,50-1,00
Aminoetansulfonovaya acid0,02-1,20
Distilled waterRest



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a novel chemically stable antioxidant compound which contains a lipophilic cationic moiety linked by a linking moiety to an antioxidant molecule and an anionic component for said cationic moiety, where the antioxidant compound is a mitoquinone, selected from: 10-(6'-ubiquinone)propyltriphenylphosphonium, 10-(6'-ubiquinonyl)pentyltriphenylphosphonium, 10-(6'-ubiquinonyl)decyltriphenylphosphonium, and 10-(6'-ubiquinonyl)pentadecyltriphenylphosphonium, having general formula I: or quinol form thereof, where R1, R2 and R3 denote CH3, the C atom in (C)n is saturated and n equals 3, 5, 10 or 15, and Z denotes an anionic component which is selected from a group consisting of methanesulphonate and ethanesulphonate. The invention also relates to a pharmaceutical composition for reducing oxidative stress in a cell, containing said compound and optionally containing β-cyclodextrin, a method of reducing oxidative stress in a cell and a method of producing an antioxidant compound.

EFFECT: improved properties of compounds.

25 cl, 31 dwg, 13 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound - 5-hydroxy-6-methyl-1-(thietanyl-3)pyrimidine-2,4(1H,3H)-dione of formula , which inhibits generation of active forms of oxygen and has antioxidant activity.

EFFECT: improved properties of compounds.

2 cl, 1 dwg, 1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to a novel compound - 6-methyl-1-(thietanyl-3)uracil of formula 1 , which stimulates the protective activity of phagocytes.

EFFECT: obtaining compounds which stimulate the protective activity of phagocytes.

2 cl, 1 dwg, 1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to organic chemistry and medicine and specifically to a novel compound - 6-(thietanyl-3)aminopyrimidine-2,4(1H,3H)-dione of formula (1), which inhibits lipid peroxidation.

EFFECT: obtaining a compound which inhibits lipid peroxidation.

2 cl, 1 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing stabiliser-coated nanocrystalline cerium dioxide characterised by antioxidant activity. The method involves preparing an aqueous solution of cerium salt and a stabiliser representing maltodextrin with a molar ratio of cerium to the stabiliser 1 to 1-4. Then, the prepared aqueous solution is added with drops of hydrous ammonia with stirring, and pH of the prepared solution is gradually increased to 7-8, maintained for 1-4 hours, the prepared colloidal solution of hydrous cerium nanoparticles is added with hydrous ammonia, and pH is increased to 11-12 and maintained for 1-10 hours to form a colloidal solution of cerium dioxide. Thereafter, an alcohol or ketone excess is removed and brought to the boiling point, while the formed precipitate of the non-aggregated nanoparticles of stabiliser-coated cerium dioxide, separated by decantation or filtration, washed 1-4 times in alcohol or ketone, and dried at temperature 50-80°C to constant weight. The prepared powder of the non-aggregated nanoparticles of stabiliser-coated cerium dioxide is re-dispersed in a polar solvent to form aggregation resistant sol.

EFFECT: invention provides preparing stabilised nanocrystalline cerium dioxide with a hydrodynamic diameter of 6-10 nm.

3 cl, 7 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to radiation biology, and may be used to treat a cadmium radiation injury and to produce a preparation for the cadmium radiation injury. Treating the cadmium radiation injury is ensured by the single subcutaneous administration of a composition consisting of anti-radiation therapeutic globulin and a suspension-forming fraction of bentonite, in a dose of 20-25 mg/kg of body weight that is followed by three more administrations 24, 48, 96 hours later if observing chronic heavy metal administration. The preparation is produced by dissolving the suspension-forming fraction of bentonite in anti-radiation therapeutic globulin in ratio 0.3:99.7 respectively while constantly stirred, and a solid concentration is reduced to 10%; the preparation is sterilised by filtration and then bottled 250-300 cm3 each to be closed tightly and kept at temperature 4-6°C.

EFFECT: method enables a consistent process of the preparation with enhanced therapeutic and decorporating effect ensured by the targeted delivery as a single agent with simplifying the use conditions.

3 cl, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely an agent possessing anti-inflammatory action. The agent possessing anti-inflammatory action contains as active ingredient in the form of a complex prepared of a coelomic fluid of sea urchins containing peptides and amino acids at a certain ratio of the ingredients.

EFFECT: agent possesses a manifested anti-inflammatory effect.

2 cl, 2 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is the use of L-carnosine for making a nanopreparation having antihypoxic and antioxidant activity combined with a combination of substances selected from the group of phospholipids, non-polar lipids in the following ratio, wt %: L-carnosine - 1.1-1.2, non-polar lipids such as triglycerides, cholesterol, free fatty acids, DL-α-Tocopherol - 1.2-2.5, phospholipids such as phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylethanolamine, sphingomyelin - 95.3-96.3 for preparing a drug having antihypoxic and antioxidant activity. The drug can be presented in the form of liposomes containing L-carnosine.

EFFECT: invention provides higher stability of L-carnosine and its lifetime up to three days with underlying higher effectiveness in small doses, as well as to improve the cerebral ischemia tolerance, the recovery after acute hypoxia and to increase the antioxidant status of the brain tissue.

3 cl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a method for preparing a carbon sorbent with the antibacterial properties, and to the carbon sorbent with the antibacterial properties prepared by this method. The declared method involves impregnation of the carbon hemosorbent granules in an initiator solution in N-vinylpyrrolidone at pH 7.0-7.5 and a residual pressure of 15-20 mm Hg. The hemosorbent : initiator solution in N-vinylpyrrolidone ratio is 1:1.4-2.0. Then the temperature is raised to 65-75°C, kept at that temperature for 0.5-8 hours in an inert medium and washed in water from the residual monomer at room temperature.

EFFECT: carbon sorbent with the antibacterial properties prepared by the specified method represents the round granules, contains polyvinylpyrrolidone in an amount of 4,5-5,5% and is characterised by a specific surface adsorption of less than 50 m2/g and total pore volume of less than 0,30 cm3/g.

2 cl, 2 tbl, 1 dwg, 7 ex

Antioxidant // 2481116

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an antioxidant containing a cyclolanostan derivative selected from 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol, and a lophenol derivative selected from 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol, in the concentration of min. 0.0001 wt %, as an active ingredient. The invention also concerns a method for preparing the specified antioxidant. The antioxidant may be used as a drug preparation, a food or a beverage, a food additive, a drug preparation for topical skin application.

EFFECT: mentioned antioxidant provides the inhibition of lipid peroxide formation.

28 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and medicine, particularly it is used for treating various forms and localisation of tuberculosis.

EFFECT: medicine under the present invention containing sodium aminosalicylate and dextran, and provides the effective treatment of multidrug-resistant pulmonary tuberculosis.

3 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a solution for preparing a chitosan material, methods for preparing the haemostatic material of the solution and a medical device with using chitosan fibres. The solution consists of the following ingredients in ratio of total amount of the solution, wt %: dry chitosan with a degree of deacetylation - not less than 80%: 4-8 at dry basis, an aqueous solution of a polymer or a mixture of polymers: 1-10 at dry basis, an aqueous solution of an organic acid or a mixture of organic acids in the concentration of 50 - 80% - the rest. The method for preparing the haemostatic material of the aqueous-acidic solution containing a polyelectrolyte complex of chitosan and a water-soluble polymer comprising the electrochemical treatment of the chitosan solution in an electric field with a conductive substrate. The electrospun fibres have the following characteristics: viscosity - 1.4-2.5 Pa·s, surface tension - 31-35 mN/m and electrical conductivity no more than 2.3 mSm/cm due to the use of a viscoelastic solution.

EFFECT: method enables the chitosan fibre of a thinner diameter.

45 cl, 20 dwg, 6 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of ophthalmology. Ophthalmological medication in form of eye drops, contains 0.2-0.5 wt % of disulfiram, dissolved in pharmaceutically acceptable water-based carrier, 0.5-2.0 wt % of hydroxypropyl cyclodextrin, 2.0-5.0 wt % of taurine; agent, which ensures required resin condition, containing sodium chloride, sodium monohydrophosphate and dihydrophosphate, and methylparaben (nipagin) as a preservative.

EFFECT: invention ensures effective treatment of pathological conditions of eyes, such as cataract, glaucoma, ophthalmological hypertension and traumatic injuries of cornea, extends arsenal of existing preparations in form of eye drops.

6 cl, 5 tbl, 2 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to food and pharmaceutical industry, namely the production of biologically active additives used for prevention of the conditions caused by vitamin and mineral deficiency, i.e. a powder for solution. The vitamin-mineral product contains a prebiotic (either sorbitol, or isomalt, or lactulose, or inulin), citric acid, a flavour, vitamins and minerals - retinol palmitate, alpha-tocopherol acetate, ascorbic acid, colecalciferol, nicotinamide, zinc, iodine, iron, selenium. The product represents a powder of weight 2.0±0.3 g.

EFFECT: vitamin-mineral product according to the invention is characterised by dosage uniformity, storage stability, bioavailability and neutral taste.

4 cl, 8 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: claimed is application of levodopa and carbidopa for preparation of medication, intended for treatment of Parkinson's disease; or for treatment of sleep malfunction in patients with Parkinson's disease, for treatment of motive activity malfunction in patients with Parkinson's disease (versions), where medication contains levodopa and carbidopa in pharmaceutically effective quantity for continuous introduction into intestine for time period, which constitutes 24 h per day or more than one day. Sleep rating scale of patients with Parkinson's disease increased by 130% on the second night after starting twenty-four-hour introduction and remained within two following years.

EFFECT: twenty-four-hour introduction of medication replaces frequent per oral intake of medications, makes it possible to reach claimed prescriptions, with preservation of stable response to on medication introduction, which is not accompanied by development of clinically significant tolerance or side effects.

17 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary, namely to veterinary mycology, bacteriology and parasitology. Complex medication for treating dogs and cats with cutaneous mycoses, bacterioses and acaroses includes as active and auxiliary components (wt %): chlorhexidine digluconate - 0.05-0.075; cypermethrin - 10.0-15.0; tetramethrin - 1.5-2.25; pyperonyl butoxide - 10.0-15.0; dimethyl sulfoxide - 15.0-22.5; polyethylene glycol M-200 or M 400 - 10.0-15.0; glycerol - 10.0-15.0, 1,2-propylene glycol - the remaining part.

EFFECT: medication has complex effect, without staining skin and its derivatives, is easily washed away with water, is efficient at temperature from minus 30 to plus 30°C and higher, has 2-year long storage term.

9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to therapeutic preparations of mumiyo. The therapeutic preparation which contains purified mumiyo, grapefruit citrosept, edible glycerol, ethanol and water at specific proportions.

EFFECT: preparation has a prolonged shelf life.

8 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed are: application of silibinin component of general formula (I) for obtaining medication for parenteral introduction for trweatment of viral hepatitis, with medication optionally containing cyclodextrin and/or phospholipid, and set of similar purpose, which includes said silibinin component and other medication, representing one or several pharmaceutical agents from: arginine, glutamate, silymarin, citiolone, epodemiol, ornithine oxoglurate, tidiacic arginine, myoinosite, methionine and N-acetyl methionine, choline, ornithine aspartate, cyanidanol, thiopronin, betaine, cyanocobalamin, leucine, levolose, acyclovir, idoxuridine, vidarabine, ribavirin, ganciclovir, famciclovir, valaciclovir, cidofovir, penciclovir, valganciclovir, brivudin, interferon. Medication preferably does not contain silidianin, and/or silicristin, and/or isosilibinin.

EFFECT: reduction of viral strain and reactivation of patients after parenteral introduction of claimed silibinin component.

21 cl, 12 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to pharmaceutical industry, namely to stable water calcium gluconate solution for injections. Said stable water calcium gluconate solution for injections contains 0.5-1 wt % of succinic acid as stabiliser, content of calcium gluconate constituting 10 wt %.

EFFECT: increased stability of calcium gluconate solution, increased term of its storage, increased resistance to low temperatures and mechanical impact.

4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and deals with pharmaceutical composition of anti-tumor action, its obtaining and perfusion solution. Essence of invention lies in the following: solution contains taxane derivatives in surface-active layer. Said solutions are used for preparation of perfusion solutions. Method of solution obtaining lies in dissolution of active substance in ethanol and introduction of surface-active substance.

EFFECT: invention makes it possible to reduce dose of active substance, reduce ethanol concentration.

8 cl, 1 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine and may be used to study the stimulation of the reparative processes in tissues of an involved joint. That is ensured by simulating the intra-articular fracture of the cotyloid cavity. The stimulation involves the restoration of anatomic relationships in the joint, the stabilisation thereof with an external fixation apparatus. Later, starting from the second postoperative day, a solution or a mixture of solutions is introduced drop-by-drop into the joint cavity for 3-5 days. Differentiating in the osteoblastic direction and forming a preferential bone fusion requires a mixture of officinal solutions of 40% glucose, 5% ascorbic acid, autologous blood plasma, taken in a volume ratio of 1:2:7 to be introduced. For the purpose of the fibroblast differentiation and formation of a preferential connective tissue fusion, a mixture of officinal solutions of 5% glucose and 5% ascorbic acid in the volume ratio 1:1 is introduced. Differentiating in the chondroblastic direction and forming a preferential cartilage fusion are ensured by introducing officinal 0.9% sodium chloride solution.

EFFECT: method provides the targeted regulation of the reparative processes in tissues of the involved joint.

3 dwg, 3 ex

Up!